Brief: Equillium Reports Third Quarter 2022 Financial Results, Provides Corporate, Clinical Updates
Brief: Equillium Announces Initiation Of Phase 2 Study Of Eq101
Equillium Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Equillium Announces Initiation Of Phase 1 Study Of Eq102, A First-In-Class Multi-Cytokine Inhibitor Of Il-15 And Il-21 Targeting Celiac Disease
U.S. RESEARCH ROUNDUP- Biogen, Generac Holdings, Luminar
U.S. RESEARCH ROUNDUP-Charter Communications, Guild Holdings, Waste Management
Brief: Equillium Announces Interim Results From EQUALISE Study
U.S. RESEARCH ROUNDUP-Alignment Healthcare, Comerica, M&T Bank Corp
U.S. STOCKS ON THE MOVE-Pinterest, Aemetis, Walmart
U.S. STOCKS ON THE MOVE-Twitter, ChargePoint, IMAX
Metacrine up on buyout offer from Equillium
Brief: Equillium To Acquire Metacrine In All-Stock Transaction
Brief: Equillium Reports Q2 2022 Results
Equillium Inc reports results for the quarter ended in March - Earnings Summary
Brief: Equillium Reports Q1 2022 Financial Results
Equillium Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Equillium Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate & Clinical Development Updates
Equillium Inc reports results for the quarter ended in December - Earnings Summary
Equillium Inc expected to post a loss of 34 cents a share - Earnings Preview